Primary Sclerosing Cholangitis | Executive Insights | US |2019
MARKET OUTLOOK
Primary sclerosing cholangitis (PSC) is a chronic, idiopathic cholangiopathy that can progress to cirrhosis, end-stage liver disease, hepatobiliary cancer, and/or colon cancer. The median age of diagnosis is 42 years, and it is more common in men than in women. Despite the severity of PSC, no therapies are approved to treat it. Current treatment with UDCA and fenofibrates offers some clinical benefit but does not prevent the progression to liver cirrhosis or cholangiocarcinoma. However, several therapies with novel mechanisms of action are in development to treat PSC and will be used first line if they prove safe and efficacious. These therapies will capitalize on the immense unmet need in this space.
QUESTIONS ANSWERED
- What are the key areas of unmet need and opportunity in the PSC therapy market?
- What is the prevalence of PSC in the United States?
- How are PSC patients currently treated in the United States?
- What therapies are in development for PSC?
- How does each current and future player influence the market, and how will this scenario change in the future?
- What are the key drivers and limiters of the PSC therapy market?
CONTENT HIGHLIGHTS
- Geography: United States
- Primary Research: Three KOL interviews in December 2019
- Key Companies Covered: Cymabay, Gilead, Intercept Pharmaceuticals, Dr. Falk Pharma, High Tide Biopharma, Acorda Therapeutics, Immunic
- Drugs Covered: Seladelpar, cilofexor, norursodeoxycholic acid, Ocaliva, HTD 1801, timolumab, vidofludimus calcium
PRODUCT DESCRIPTION
Executive Insights provides indication-specific market intelligence with world-class epidemiology, keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.
